Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Magic bullets hit the target
3. Advances in monoclonal antibody therapy
4. Antibodies for cancer immunotherapy
5. T-cell leukemia/lymphoma - an orphan disease
6. Targets for receptor-directed therapy
7. The IL-2 receptor
8. 3 cytokine binding membrane components
9. Shared chains
10. Distribution of IL-2 receptors
11. Soluble IL-2R-alpha in pateints with ATL
12. Candidates for IL-2 receptor-directed therapy
13. Allograft protocols
14. Soluble IL-2R levels in autoimmune diseases
15. Adult T cell leukemia/lymphoma
16. IL-2 receptor expression in ATL
17. Murine model of ATL
18. Leukemia treatment with various antibodies
19. Effect of HAT: FcR intact vs. FcR knockout mice
20. Materials to eliminate IL-2R alpha expressing cells
21. IL-2R alpha as a target for immunotherapy of ATL
22. Daclizumab (humanized anti-Tac)
23. Anti-Tac therapy of ATL
24. Remission after IL-2R-alpha-directed therapy
25. Daclizumab therapy of patients with MS
26. Changes in CE lesions during daclizumab therapy
27. Daclizumab can decrease renal allograft rejection
28. Anti-tumor effect enhanced by combination therapy
29. Arming of cytokines with toxins or radionuclides
30. Effect of flavopiridol and HAT in an ATL model
31. Anti-Tac(Fv)-PE38 (LMB2)
32. Response of HCL to LMB2
33. Issues for effective radioimmunotherapy
34. Alpha/beta emitters in radioimmunotherapy
35. Materials to eliminate IL-2R alpha expressing cells
36. Radioimmunotherapy of ATL with 90Y-anti-Tac
37. 90Y-anti-Tac effective therapy for ATL
38. 111In anti-Tac
39. Limitations of intact antibodies
40. Pretargeting approach
41. Biodistribution of In-11-HAT in nude mice
42. Biodistribution of pretargeted In-DOTA-biotin
43. Effects of 213Bi anti-Tac/SA pretarget therapy
44. Survival (fusion protein, Y-90, SUDHL-1)
45. Discovery of IL-15
46. The structure of human IL-15
47. IL-15 vs. IL-2 cytokine interaction
48. IL-2/15 roles in the life and death of lymphocytes
49. Control of IL-15 expression
50. Abnormalities of IL-15 expression
51. The role of IL-15 in celiac disease
52. HAT inhibita IL-2 ; Mik beta1 inhibits IL-15
53. Humanized Mik beta1 prolongs allograft survival
54. Immunoregulatory negative checkpoint blockade
55. CD4+ CD25+ negative regulatory Tregs
56. mAb PC61 facilitates tumor rejection
57. IL-15 induced STAT-mediated gene regulation
58. Strategies to interfere with cytokine signaling
59. Summary
60. Concluding remarks

Topics Covered

• Structure and function of IL-2 receptor
• Disorders of IL-2 receptor expression in disease
• IL-2R alpha-directed monoclonal antibody mediated therapy of leukemia and autoimmune diseases
• Anti-IL-2E alpha monoclonals armed with toxins or radionuclides
• IL-15 and its use of the IL-/IL-15 beta receptor
• IL-2/IL-15 R beta receptor directed therapy for leukemia and autoimmune diseases
• The IL-2R alpha as a target in the elimination of CD4+ CD25+ T-regs (suppressor cells)

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Cancer
• Immunology

Therapeutic Areas:

• Immunology & Inflammation
• Oncology

Talk Citation

Waldmann, T. (2007, October 1). Anti-IL-2 receptor antibodies as models for cancer therapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/KTPH3659.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Archived on June 13, 2019

Financial Disclosures

• Prof. Thomas Waldmann has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.